Evropska unija -
slovenščina -
EMA (European Medicines Agency)
nucala
glaxosmithkline trading services - mepolizumab - astma - zdravila za obstruktivne pljučne bolezni, - severe eosinophilic asthmanucala is indicated as an add-on treatment for severe refractory eosinophilic asthma in adults, adolescents and children aged 6 years and older. chronic rhinosinusitis with nasal polyps (crswnp)nucala is indicated as an add-on therapy with intranasal corticosteroids for the treatment of adult patients with severe crswnp for whom therapy with systemic corticosteroids and/or surgery do not provide adequate control. eosinophilic granulomatosis with polyangiitis (egpa)nucala is indicated as an add-on treatment for patients aged 6 years and older with relapsing-remitting or refractory eosinophilic granulomatosis with polyangiitis (egpa). hypereosinophilic syndrome (hes)nucala is indicated as an add-on treatment for adult patients with inadequately controlled hypereosinophilic syndrome without an identifiable non-haematologic secondary cause.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
nucala 100 mg prašek za raztopino za injiciranje
glaxosmithkline trading services limited - mepolizumab - prašek za raztopino za injiciranje - mepolizumab 100 mg / 1 viala - mepolizumab
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
nucala 100 mg prašek za raztopino za injiciranje
glaxosmithkline trading services limited - mepolizumab - prašek za raztopino za injiciranje - mepolizumab 100 mg / 1 viala - mepolizumab